182951
Megan's Law: A public health imperative
The purpose of this paper is to provide an overview of the history of laws related to Registered Sexual Offenders (RSO's), including the Jacob Wetterling Act, Megan's Law, and the most recent Adam Walsh Act. These laws were developed to prevent sexually-based crimes based on the assumption that there is a high recidivism rate among RSO's. Studies and reports consistently find, however, have the lowest recidivism (2-13%) rate of all felons. In addition, new research is reporting that Megan's Law has not been effective at reducing sexually-based crimes. Others report that the laws restricting and monitoring RSO's are actually increasing the risk they will repeat their crimes. RSO's face many collateral consequences, such as community segregation, lack of employment, housing, separation from families and loved one's, lack of access to social services, and vigilante attacks. All of these collateral consequences make it difficult for an RSO to remain offense-free and thus decrease public safety. It is thus a public health imperative to critically explore how well these laws are working to prevent sexually based crimes.
Learning Objectives: 1. Describe the history of laws related to registered sexual offenders in the United States.
2. Discuss the recidivism rate of registered sexual offenders.
3. Evaluate the effectiveness of Megan's Law (and the Adam Walsh Act) at preventing sexually based crimes.
4. Discuss the collateral consequences facing registered sexual offenders and the public as a result of Megan's Law (and the Adam Walsh Act).
Keywords: Sexual Assault, Policy/Policy Development
Presenting author's disclosure statement:Qualified on the content I am responsible for because: I have PhD in Health Promotion and Disease Prevention and have been the sole researcher on the study/abstract I am submitting.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines,
and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed
in my presentation.
|